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  Background:  The 5-hydroxytryptamine type 3 (5-HT3) receptor is a member of the Cys-loop superfamily of ligand-gated ion 
channels (LGICs) and modulated by pharmacologic relevant concentrations of volatile anesthetics or n-alcohols like most receptors 
of LGICs.  The goal of this study was to reveal whether the site-directed single mutations of E-106, F-107 and R-222 in 5-HT3 
receptor may affect the anesthetic modulation of halothane known as positive modulator. 
  Methods:  The wild-type and mutant receptors, E106D, F107Y, R222F, R222V, were expressed in Xenopus Laevis oocytes 
and receptor function was assessed using two electrode voltage clamp techniques. 
  Results:  E106D, F107Y, R222F, R222V mutant 5-HT3A receptors were functionally expressed.  F107Y mutant 5-HT3A receptors 
displayed decreased sensitivity to 5-HT compared to the wild type 5-HT3A receptor (P ＜ 0.05).  Halothane showed positive modu-
lation in both wild and F107Y mutant 5-HT3A receptors but F107Y mutant 5-HT3 receptor showed greater enhancing modulation 
comparing to wild-type receptor.  Meanwhile, R222F and R222V mutant 5-HT3 receptor lost positive modulation with 1 and 2 
MAC of halothane.  Most interestingly, positive modulation by halothane was converted into negative modulation in E106D mutant 
5-HT3A receptor. 
  Conclusions:  The present study implicate the amino acid residues known for agonist binding and linking agonist binding to 
channel gating might also have important role for anesthetic modulation in 5-HT3A receptor.  (Korean J Anesthesiol 2009; 56: 
66～73)
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INTRODUCTION
  The 5-hydroxytryptamine type 3 (5-HT3) receptor is a mem-
ber of the Cys-loop superfamily of ligand-gated ion channels 
(LGICs) that includes the nicotinic acetylcholine, glycine, and 
[gamma]-amino butyric acid type A (GABAA) receptors.1) 
Among the five subunits (A-E) cloned to date, 5-HT3A and 
5-HT3B subunits have been demonstrated to have functional 
significance in the central and peripheral nervous systems. The 
5-HT3B subunit must be coexpressed with the 5-HT3A subunit 
to be functional in peripheral nervous system, whereas the 
5-HT3A subunit can form functional channels homomerically 
and such a homomer is predominantly expressed in central and 
peripheral nervous systems.2-4) 
  Receptors in superfamily of LGICs are comprised of a pen-
tameric arrangement with each subunit containing a large ex-
tracellular N-terminal domain, four transmembrane domains 
(TM1-TM4), a large intracellular loop between TM3 and TM4, 
and an extracellular C-terminal domain.5) The structure and 
function of LGICs is under intense investigation but still am-
biguously defined. The ligand binding sites are thought to be 
located in the extracellular N-terminal domain at subunit-sub-
unit interface, and the channel pore is believed to be formed 
by TM2.5) Activation of LGICs involves that the binding of 
neurotransmitter to the closed, resting state receptors triggers a 
complex conformational change which results in the opening 
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the channels. Many electrophysiological studies of volatile an-
esthetics have focused on their effects on LGICs. Like most 
receptors of LGICs, 5-HT3 receptor is modulated by pharmaco-
logic relevant concentrations of volatile anesthetics or 
n-alcohols.6,7) Most volatile anesthetics, such as desflurane, iso-
flurane, halothane, enflurane and methoxyflurane potentiate 
5-HT3 receptor at their human alveolar concentrations.7-11) 
However, sevoflurane and two gaseous anesthetics (nitrous ox-
ide, xenon) and intravenous anesthetics, such as pentobarbital 
and propofol, inhibited the 5-HT3A receptor.11-13) Studies of chi-
mera or single residue mutagenic recombinant receptors of 
LGICs suggested that the function of LIGS was characterized 
by the N-terminal domain rather than transmembrane domains 
and C-terminal domain and channel gating sites are located in 
TM2.14) The majority of study of anesthetic modulation in 
LGICs were focused in amino acid residues in TM2 associated 
with the channel gating.15-19) But for the receptor to be acti-
vated, several amino acids in the proximal area of TM1 are 
also important for agonist recognition (glutamate 106 and phe-
nylalanine 107 in N-terminal area) and possible coupling 
(arginine 222 in pre TM1 domain) between agonist binding 
and gating.20-22) In chimeric receptor of N-terminal domain 
from nACh alpha 7 receptor and the TM and C-terminal do-
mains from 5-HT3 receptor, modulation by isoflurane was in-
volved the N-terminal domain of the receptor, which means 
that the anesthetic modulation in receptor may be also charac-
terized by the N-terminal domain.23) Considering that three 
amino acids in the proximal to TM1 domain of 5-HT3 receptor 
are important for agonist binding (glutamate 10621) and phenyl-
alanine 10720)) and coupling of agonist binding and channel 
gating (arginine 22222)), the anesthetic modulatory effect might 
be affected by the mutagenesis of the N-terminal domain of 
5-HT3 receptor, especially glutamate 106 and phenylalanine 107 
known for agonist binding sites, and the arginine 222 in the 
pre-TM1 domain known for linking agonist binding to channel 
gating of 5-HT3 receptor. 
  So this study was intended to reveal whether the mutations 
of E-106, F-107 and R-222 at the N-terminal domain and 
pre-TM1 domain may affect the anesthetic modulation of hal-
othane known as positive modulator in 5-HT3 receptor ex-
pressed in Xenopus Laevis oocytes using two electrode voltage 
clamp techniques.
MATERIALS AND METHODS 
Site-directed mutagenesis of the 5-HT3A cDNA
  A cDNA isolated from the mouse 5-HT3A receptor was gen-
erously provided by Dr. Jay Yang (Columbia University, 
USA). Seven kinds of mutant 5-HT3A receptor were constructed. 
Glutamate (E) 106 was mutated into aspartate (E106D) or ty-
rosine (E106Y), phenylalanine (F) 107 into tyrosine (F107Y) or 
serine (F107S), and arginine (R) 222 into proline (R222P), 
phenylalanine (R222F) and valine (R222V), respectively. 
    For site-directed mutagenesis, sense and antisense primer 
oligonucleotides used were as following;
E106D
  Sense primer oligonucleotides:
  5’CTGACATTCTCATCAATGACTTTGTGGACGTGGGG3’
  Anti sense primer oligonucleotides:
  5’CCCCACGTCCACAAAGTCATTGATGAGAATGTCAG3’
E106Y
  Sense primer oligonucleotides:
  5’TCCCTGACATTCTCATCAATTACTTTGTGGACGTGG-
GGAAG3’
  Anti sense primer oligonucleotides:
  5’CTTCCCCACGTCCACAAAGTAATTGATGAGAAT-
GTCAGGGA3’
F107Y
  Sense primer oligonucleotides:
  5 ’ T G A C A T T CT C A T C A A T G A G T A C G T G G A C G T G-
GGGAAGTC3’
  Anti sense primer oligonucleotides:
  5’GACTTCCCCACGTCCACGTACTCATTGATGAGAA-
TGTCA3’
F107S
  Sense primer oligonucleotides:
  5’CCTGACATTCTCATCAATGAGAGCGTGGACGTGG-
GGAAGTC3’
  Anti sense primer oligonucleotides:
  5’GACTTCCCCACGTCCACGCTCTCATTGATGAGAAT-
GTCAGG3’
R222P
  Sense primer oligonucleotides:
  5’CGTGATCATCCGCCGGCCACCTTTATTCTATGCAG-
TCAG3’
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  Anti sense primer oligonucleotides:
  5’CTGACTGCATAGAATAAAGGTGGCCGGCGGATGA-
TCACT3’
R222F
  Sense primer oligonucleotides:
  5’ACGTGATCATCCGCCGGTTCCCTTTATTCTATGCA-
GTCAGC3’
  Anti sense primer oligonucleotides:
  5’GCTGACTGCATAGAATAAAGGGAACCGGCGGAT-
GATCACGT3’
R222V
  Sense primer oligonucleotides:
  5’ACGTGATCATCCGCCGGGTACCTTTATTCTATGCAG-
TCAGC3’
  Anti sense primer oligonucleotides:
  5’GCTGACTGCATAGAATAAAGGTACCCGGCGGATGA-
TCACGT3’
  Point mutation of the mouse 5-HT3A receptor was accom-
plished using a Quickchange site-directed mutagenesis kit 
(Stragene, USA) using the 20−25 bp oligonucleotide sized 
primer via Generunner v3.02 (Hastings software Inc., USA). 
The successful incorporation of mutation was verified by se-
quencing the clones using an automated DNA sequencer 
(Genetic Analyzer 3100, USA). 
Expression of 5-HT3A receptors into Xenopus laevis oocytes
  Wild-type and point mutant mouse 5-HT3A receptor cDNAs 
were subcloned into a custom oocyte expression vector, 
pCR-Script SK(＋) and linearized by SalⅠdigestion, to prepare 
template cDNA. cRNA was synthesized in vitro using T3 
RNA polymerase (Message Machine, Ambion, USA) following 
manufacturer’s recommended protocol. 
  All procedures for animal care and use were approved by 
the Yonsei University committee on Animal Care. Frogs were 
anesthetized by cold-emersion anesthesia with 0.15% 3-p-ami-
nobenzoic acid for 30 min. Through a small incision in the 
frog’s abdomen, ovarian lobes were placed in modified Barth’s 
Solution (MBS) (NaCl 88 mM, KCl 1 mM, CaCl2 0.41 mM, 
Ca(NO3)2 0.33 mM, NaHCO3 2.4 mM, MgSO4 0.83 mM, Na 
pyruvate 250 mM, HEPES 5 mM, pH 7.4, theophylline 0.5 
mM, Penicillin 10 U/ml, streptomycin 10 U/ml, gentamycin 10 
U/ml). Ovarian lobes were manually dissected into clumps of 
4 to 10 oocytes and then treated with 1.5 mg/mL collagenase 
IA in Ca2＋ free frog Ringer’s solution (NaCl 120 mM, KCl 2 
mM, HEPES 5 mM, pH 7.4) for 30 min to remove the fol-
licular-cell layer. After the oocytes were rinsed several times, 
approximately 50 ng of cRNA was injected into stage Ⅴ-Ⅵ 
oocytes by using a microinjector (Nanojector, Drummond 
Scientific, USA). Oocytes were incubated in modified MBS 
(NaCl 88 mM, KCl 1 mM, CaCl2 0.41 mM, Ca(NO3)2 0.33 
mM, NaHCO3 2.4 mM, MgSO4 0.83 mM, Na pyruvate 250 
mM, HEPES 5 mM, pH 7.4, theophylline 0.5 mM, Penicillin 
10 U/ml, streptomycin 10 U/ml, gentamycin 10 U/ml) at 18oC 
for 48−96 hr. Incubation medium was changed daily.
Two electrode voltage clamp recording 
  After 48−96 hour incubation period at 18oC, an oocyte was 
placed into a Plexiglas recording chamber approximately 300 
μL in volume and continuously perfused with 1.8 mM Ca2＋ 
frog Ringer’s solution (NaCl 120 mM, KCl 2 mM, HEPES 5 
mM, CaCl2 1.8 mM, pH 7.4) at 3−7 mL/min. The oocyte 
was penetrated with two glass electrodes with resistance of 1−
3 MΩ when filled with 3 M KCl solution. Two electrode 
voltage clamp recordings at −50 mV were obtained with an 
Oocyte Clamp (OC 725C, Warner Instruments, USA). 
  After 5-HT dose response curves were taken from both wild 
and mutant receptors expressed functionally, the effects of clin-
ical doses of halothane, 1 and 2 MAC, on 5-HT-mediated cur-
rents were compared, in which 5-HT concentration that evokes 
approximately 20% of the maximal peak current for each re-
ceptor was used (EC20 concentration). 
  Oocytes were preincubated with halothane for 2 min prior to 
application of 5-HT for 20−30 s until the peak current 
reached. Saturated solutions of halothane were prepared by 
bubbling of halothane with microbubbler into a sealed bottle of 
recording solution at a gas flow rate of 200 mL/min for more 
than 30 min. The 100% O2 was passed through the agent spe-
cific calibrated vaporizer. Each experiment was preceded and 
followed by a control application of 5-HT, both to normalize 
data and to ensure the reversibility of drug-induced modulation 
of currents. Cumulative desensitization was excluded by con-
firming that the control response (within 90% recovery) was 
induced. For analysis, the average of these two measurements 
was used as the control. A 5−30 min recovery period was al-
lowed after each application of agonist (with or without anes-
thetic). Experiments were repeated in at least four oocytes. 
  The bath solution exchange time constant was approximately 
0.5 s and orders of magnitude slower than the biochemical in-
teractions between ligand and receptors. The timing of drug 
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Fig. 1. Concentration response curves for 5-HT in wild type (WT) 
and mutant 5-HT3A receptors. The F107Y mutant 5-HT3A receptor 
decreased the sensitivity to agonists. I and Imax are the current at 
a given 5-HT concentration and the maximal current, respectively. 
Each data point represents mean ± SEM from 5−8 cells.
Fig. 2. Representative current tracings, responses to 5-HT with and 
without halothane in wild-type and mutant 5-HT3A receptors. 
Oocytes were first preincubated with halothane for 2 min prior to 
application of 5-HT. Peak currents were recorded and compared to 
halothane-free controls.
Table 1. Summary of the Properties of the Wild Type (WT) and 
Mutant 5-HT3A Receptors Expressed in Xenopus Laevis Oocytes
Receptor 5-HT EC50 (µM) Hill coefficient Imax (µA)
WT
E106D
F107Y
R222F
R222V
1.29 ± 0.18
1.41 ± 0.21
 7.47 ± 0.85*
0.61 ± 0.16
0.50 ± 0.08
2.12 ± 0.08
 1.22 ± 0.16*
2.43 ± 0.17
 0.75 ± 0.06*
2.24 ± 0.19
3.84 ± 0.36
1.05 ± 0.21
7.39 ± 1.51
0.38 ± 0.09
3.51 ± 0.74
EC50, Hill coefficient (n), and Imax of the 5-HT concentration- 
response curves for WT and various mutant receptors are listed, 
expressed as mean ± SEM of 4−8 oocytes. These values were 
obtained by fitting the data to the equation given in the section of 
"Materials and Methods." The values for mutant receptor were 
compared with those of the WT receptor, and the statistical sig-
nificance was calculated using ANOVA with Tukey test for multi-
ple comparisons. *: P ＜ 0.05 compared with WT.
application and current digitization were controlled by Clampex 
v 5.2 (Axon Instruments, USA).
  5-HT (serotonin), collagenase IA, and almost all the chem-
icals were purchased from Sigma-Aldrich (USA). Halothane 
was purchased from Sigma-Aldrich (USA). 
Data analysis 
  Peak currents induced by the drug applications were meas-
ured and concentration- response curves were fit (Sigmaplot v 7.0; 
SPSS Inc., USA) to the equation I/ Imax=Cn/(Cn ＋ EC50n) 
where I is normalized peak current form serotonin, and Imax is 
maximal normalized peak current. C is the concentration of se-
rotonin, n is Hill coefficient and EC50 is the concentration at 
which half-maximal peak current is induced. 
  The inhibitory or potentiating effects of halothane were pre-
sented as percentage in comparison with the currents induced 
by serotonin EC20. 
  The values represented mean ± SEM. Statistical analysis was 
performed using ANOVA with Tukey test for multiple compar-
ison and Mann-Whitney U test in appropriate. P ＜ 0.05 was 
considered significant. 
RESULTS
Functional characterization of the wild-type and mutant 
5-HT3A receptors
  E106D, F107Y, R222F, R222V mutant 5-HT3A receptors 
were functionally expressed but E106Y, F107S, R222P mutant 
5-HT3A receptor were not functionally expressed even with 
1mM 5-HT. Fig. 1 shows 5-HT concentration-response relation-
ships for currents in wild and mutant 5-HT3A receptors. The 
5-HT EC50 values, Hill coefficients and Imax obtained from 
analyses of these concentration-response curves are listed in 
Table 1. F107Y mutant receptor displayed decreased sensitivity 
to 5-HT comparing to the wild receptor, with about 6 - fold 
rightward shifts observed. Hill coefficients for 5-HT were sig-
nificantly decreased in E106D and R222F mutant receptors 
compared with wild-type 5-HT3A receptors.
Modulation of 5-HT EC20-induced currents by halothane 
according to wild-type and mutant 5-HT3A receptors
  Halothane itself did not induce any current in wild and mu-
tant receptors.
  Fig. 2 illustrates current tracings, responses to 5-HT with 
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Fig. 3. Effects of halothane on 5-HT-induced currents in the 
wild-type and mutant 5-HT3A receptors. In E106D mutant 5-HT3A 
receptor, halothane did not potentiate but inhibited the 5-HT-in-
duced currents. Values are percent change of the control response 
without halothane. Negative numbers indicate percentage of inhibition. 
Data from more than 8 oocytes were expressed as mean ± SEM. 
*: P ＜ 0.05 compared with the value of wild 5-HT3A receptor.
and without halothane in wild-type and mutant 5-HT3A 
receptors. 
  Fig. 3 depicts the modulation of 5-HT EC20-induced currents 
by halothane. The F107Y mutant 5-HT3A receptor increased 
positive modulation by halothane. Both R222F and R222V mu-
tant 5-HT3A receptor have little influence on positive modu-
lation by halothane. In marked contrast of these results, E106D 
mutant 5-HT3A receptor was negatively modulated by 
halothane. 
DISCUSSION
  In present study, we investigated the effects of single muta-
tion of three amino acid residues (E106, F107, R222), located 
in the proximal to transmembrane domain1 of 5-HT3A receptors 
which are involved in agonist binding and linking the agonist 
binding to channel gating, on the modulation of the inhalation 
anesthetics in 5-HT3A receptor. 
  LGICs seem to be the target receptors of anesthetic action. 
Most studies of anesthetic mechanism are conducted in nACh 
receptor or GABAA receptors. Along with anesthetic mecha-
nism on LGICs, anesthetics induced side effect such as post-
operative nausea and vomiting has focused on the 5-HT3A 
receptor. LGIC member subunits share significant sequence ho-
mology and consists of a large, extracellular N-terminal do-
main, four transmembrane α-helical segments, and an intra-
cellular component.22,24,25) There have been many studies to 
identify amino acid residues critical for LGIC assembly, ago-
nist affinity, and conductance.5,22,26) From these studies, ex-
tracellular N-terminal domain is responsible for agonist binding, 
TM2 domain lines the channel pore and forms the channel 
gate, and the pre-TM1 region and the TM2-TM3 loop of 
5-HT3A receptor are implicated in the coupling process between 
agonist binding and channel gating.22,25) Also there has been 
suggested that anesthetic binding site of LGICs exists in trans-
membrane domain.24,27-29) At present, there have been many 
studies on anesthetic modulation in anesthetic or alcohol bind-
ing pocket located in TM2 and/or TM3.15-18) According to 
these studies, anesthetics and alcohols concentrate in water-fil-
led protein clefts, altering the flexibility of the protein and 
hence protein function. Miyazawa et al. reported that the L257 
residue of the α subunit of the Torpedo nACh receptor 
(analogous to S267 in the α1 glycine receptor and L270 in 
the 5-HT3A receptor) faces away from the pore and towards 
the other three α-helical transmembrane domain, presumably 
forming part of a water-filled cavity in which anesthetics can 
bind. Mihic et al.19) demonstrated that mutations of two amino 
acids, serine 267 in TM2 and alanine 288 in TM3 blocked al-
cohol and anesthetic enhancement of glycine receptor-mediated 
currents. Mutations of leucine-293 or isoleucine-294 in TM2 of 
5-HT3A receptor alter alcohol modulatory actions.17,18) Also phe-
nylalanine-269 and leucine-270 in TM2 markedly affected alco-
hol and anesthetic enhancement of 5-HT3A receptor function.15) 
Mutation of a single amino acid in the extracellular trans-
membrane segment 2 domain induces resistance to ketamine 
inhibition in the α7 nicotinic receptor and sensitivity to in-
hibition in the 5-HT3A receptor.16) For LGICs to be activated, 
signal transduction travels from the agonist binding to con-
formational change of the channel. But there have been few 
studies of the functional role of amino acid residues located in 
the proximal site to transmembrane domain on anesthetic mod-
ulation although these sites are involved in the initial process 
of the signal transduction pathway. We raised the questions 
that mutation of single amino acid residues, especially gluta-
mate 10621) and phenylalanine 10720) thought to be important 
for agonist binding and arginine 22222) for linking of agonist 
binding to channel gating, might affect the anesthetic modu-
lation in the 5-HT3A receptor.
  We constructed 7 individual mutants. Among them E106D, 
F107Y, R222F, R222V mutant 5-HT3A receptors were function-
ally expressed but E106Y, F107S and R222P mutant 5-HT3A 
receptors were not functionally expressed. The functional char-
Kim et al：Halothane modulation in 5-HT3AR
71
acteristics of expressed wild, E106D, F107Y and R222F mu-
tant 5-HT3A receptors, were comparable with others.20-22,30) 
F107Y mutant 5-HT3A receptors displayed decreased sensitivity 
to 5-HT compared to the wild type 5-HT3A receptor with 6 
fold rightward shift observed (P ＜ 0.05). While the Hill co-
efficient of 2.12 ± 0.08 in wild type receptor indicated pos-
itive cooperativity of agonist activation, both E106D and 
R222F mutant 5-HT3A receptors lost a positive cooperativeness 
(E106D, 1.22 ± 0.16; R222F, 0.75 ± 0.06 vs. wild type, 2.12 
± 0.08, P ＜ 0.05). Although functional characteristics of 
R222V mutant 5-HT3 receptor were not compared with others, 
it certainly constructed functional channel to the agonist, 5-HT. 
  To find the modulation effect of halothane in wild 5-HT3A 
receptor and various mutant 5-HT3A receptor, we preapplied the 
saturated halothane for 2 minutes with 1 and 2 MAC, known 
as positive modulator to 5-HT3A receptor, before applying 
5-HT (EC20 taken from each dose response plot) (Fig. 3). 
Stevens et al.7) noted that anesthetic modulation in 5-HT3A re-
ceptor exhibits a dependence on molecular volume and volatile 
anesthetics except sevoflurane enhanced the 5-HT-induced 
currents. In their study, desflurane and halothane enhanced 
modulation in wild 5-HT3A receptor similar to this study, al-
though the degrees of enhancing the 5-HT induced currents 
were greater than those of this study. This difference could be 
explained from that they used EC10 concentration of 5-HT 
while this study used EC20 concentration of 5-HT and we just 
pre-applied the volatile anesthetic before 5-HT applying so that 
remaining anesthetic concentrations in the measuring bath must 
be diluted. Halothane showed positive modulation in both wild 
and F107Y mutant 5-HT3A receptors and F107Y mutant 5-HT3 
receptor showed greater enhancing modulation comparing to 
wild receptor with 1 MAC of halothane. Meanwhile R222F 
and R222V mutant 5-HT3 receptor lost positive modulation 
with 1 and 2 MAC of halothane. Most interestingly, positive 
molulation by halothane was converted into negative modu-
lation in E106D mutant 5-HT3 receptor (Fig. 3). The direction 
of modulation by halothane from mutagenesis of agonist bind-
ing sites, glutamate 106 and its adjacent phenylalanine 107 
displayed differently. Especially mutation of glutamate into as-
partate resulted in shortening of methylene group without alter-
ing its polarity. Interestingly, the shortening by methylene 
group at the side chain of leucine into valine in TM2 domain 
lost volatile anesthetic’s positive modulation.15) But it is not 
probably rational that simple shortening by methylene group in 
amino acid residues of agonist binding site or channel pore 
site determine the anesthetic modulatory direction.
  Although this study has limitation for getting kinetic in-
formations from constructed receptors, normalized current trac-
ings of 5-HT induced in presence or absence of halothane dis-
played identical current shapes in all the constructed receptors 
except F107Y mutant 5-HT3A receptor. In F107Y mutant 
5-HT3A receptor, there was rapid desensitization during 5-HT 
application in presence of halothane. On the contrary, 5-HT- 
induced gating in F107Y mutant 5-HT3A receptor expressed in 
HEK 293 cell, did not display rapid desensitization even with 
10 mM concentration of 5-HT.20) 
  The anesthetic effects on 5-HT3A receptors may not contrib-
ute to the establishment of an anesthetized state but be related 
to anesthetic induced nausea and vomiting. In vitro study, most 
volatile anesthetics, such as enflurane, halothane, isoflurane, en-
hanced 5-HT induced current in wild type 5-HT3A receptor 
with varying degree, but sevoflurane or propofol inhibited 
it.7-11,13) These findings are also noticeable in clinical studies. 
Philip et al.31) showed that the incidence of postoperative nau-
sea and vomiting after ambulatory anesthesia was lower in the 
sevoflurane group than in the isoflurane group. Raeder et al.32) 
reported that the incidence of postoperative nausea and vomit-
ing was decreased following the use of propofol rather than 
desflurane after laparoscopic cholecystectomy. 5-HT3A receptors 
in the area postrema of the brain are believed to be associated 
with anesthetic associated nausea and vomiting.33) 
  At present, several subtypes of 5-HT3 receptor were identi-
fied and recombinant 5-HT3A receptor shows most of native 
5-HT3 receptor properties. Nevertheless, it is not completely 
clear whether native 5-HT3 receptors in different brain area are 
constituted by homomeric 5-HT3A pentamer or heteromeric pen-
tamers from combination of 5-HT3A and 5-HT3B or other 
subtypes. Therefore, mechanisms of anesthetic modulation in 
5-HT3 receptor seem to be multiple and complex. It was evi-
dent from the fact that modulation by volatile anesthetic was 
decreased in 5-HT3AB receptor than in 5-HT3A receptor. 
Incorporation of 5-HT3B receptor might alter the anesthetic 
binding site or the allosteric interaction between anesthetic 
binding and channel opening.34) Furthermore, the additive ef-
fects of halothane and ethanol on the 5-HT3 receptor suggest 
the evidence that these compounds have different targeting 
sites within 5-HT3 receptor.9) But at the molecular level of 
5-HT3 receptor, anesthetic modulating sites are much more 
complicated. From this study conducted at the molecular levels 
of 5-HT3A receptor, anesthetic modulation in 5-HT3A receptor 
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were also affected by single mutagenesis of agonist binding 
sites (glutamate 106 and penylalanine 107) or presumed cou-
pling site (arginine 222) between agonist binding and channel 
gating as well as of channel pore sites or anesthetic binding 
pocket in LGICs.10,15,17-19,25,27,35)
  The underlying mechanism how anesthetics interact with the 
LGICs is assumed as an allosteric fashion.36) As shown in the 
simplified kinetic scheme involving anesthetic modulation 
mechanism, allosteric modulation of anesthetics in 5-HT3A re-
ceptors might be achieved by altering agonist binding, the 
channel gating or linking both or desensitization.
  In conclusion, this study has shown that mutation of gluta-
mate 106 into aspartate in 5-HT3A receptor changed the direc-
tion of halothane modulation from positive to negative. 
Mutations of phenylalanine 107 into tyrosine potentiated hal-
othane modulation, while mutation of arginine 222 into phenyl-
alanine or valine lost halothane modulation. These findings, 
conducted at the molecular level of 5-HT3A receptor, might in-
dicate that anesthetic modulation in 5-HT3A receptor could be 
affected by the mutation of amino acid residues important for 
agonist binding and linking agonist to channel gating as well 
as channel gating. 
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